GL1X · GenesisL1 explorer

MolNFT v1 · #99110 · protein

Discovery of potent and efficacious cyanoguanidine-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors

4LTS: “Discovery of potent and efficacious cyanoguanidine-containing nicotinamide phosphoribosyltransferase (nampt)…”. X-ray diffraction, 2 ligands (LTS, PO4), 7 pockets (best druggability 0.80). MolNFT v1 #99110 on GenesisL1: 3D…

PDB
4LTS
Type
protein
Length
945 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Nicotinamide phosphoribosyltransferase
EC
2.4.2.12
UniProt
P43490
Ligands
LTS, PO4
Pockets
7 · best druggability 0.80

Structure

x-ray diffraction · 2 distinct chains · 42% helix, 19% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ANicotinamide phosphoribosyltransferase (EC 2.4.2.12)protein47242% helix, 19% strandP43490
BNicotinamide phosphoribosyltransferase (EC 2.4.2.12)protein47342% helix, 19% strandP43490

Ligands and binding sites

  • LTS · 2-cyano-1-pyridin-4-yl-3-(4-{[3-(trifluoromethoxy)phenyl]sulfonyl}benzyl)guanidine · ligand · 2 copies · chains A, B
  • PO4 · Phosphate ion · ion · 2 copies · chains A, B
  • EDO · 1,2-ethanediol · additive · 9 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

7 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
18290.800.8389LTS, EDO, PO4
27590.790.8376PO4, LTS, EDO
36870.730.7957empty
4830.370.7714EDO
5580.360.7921empty

Interfaces

1 interface between chains.

  • A–B · 4286 Ų buried · 80 hydrogen bonds · protein-protein

Compared structures

  • 4LTS · Discovery of Potent and Efficacious Cyanoguanidine-containing Nicotinamide… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.